With stock valuations down and out, the timing may be ripe for pharma and big biotech companies to start bargain hunting.
News & Analysis: Portola Pharmaceuticals
The company's second-quarter revenue is sparking optimism for future growth.
PTLA earnings call for the period ending June 30, 2019.
The company's still struggling to transition from clinical stage to commercial stage, but it's making progress.
PTLA earnings call for the period ending March 31, 2019.
First-quarter financial results are failing to spark investor optimism on concerns over cash burn.
This commercial-stage company's success depends heavily on the demand for one drug.
PTLA earnings call for the period ending December 31, 2018.
The company's latest quarterly update is sparking optimism that sales might accelerate.
The company's struggling to make the shift to commercial-stage biotech, and recent news raises questions on when this will change.